TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06059716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous telemedicine monitoring
Description: Regular follow-up with an expert dietitian
Study: NCT05606692

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane/Ultane
Description: The sevoflurane group was maintained via sevoflurane vaporizer between 1% and 3% (target minimum alveolar concentration of 0.7-1.3).
Study: NCT04131361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided Inferior vena cava diameter dependent colloid challenge versus routine crystalloid strategy Fluid replacement
Description: The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound-guided Inferior vena cava diameter dependent colloid challenge versus routine crystalloid strategy Fluid replacement
Description: The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region.
Study: NCT05445115

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Mollie device
Description: medical device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mollie device
Description: medical device
Study: NCT04441073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lignocaine
Description: preoperative nebulization of lignocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: preoperative nebulization of normal saline (Nacl 0.9%) as a placebo
Study: NCT05224596

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw and blood-based biomarkers analyses
Description: blood-based biomarkers analyses

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw and blood-based biomarkers analyses
Description: blood-based biomarkers analyses
Study: NCT05058144

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drinkable solution
Description: the volunteer will consume the volume 300 ml of water with

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drinkable solution
Description: the volunteer will consume the volume 300 ml of water with

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Drinkable solution
Description: the volunteer will consume the volume 300 ml of water with
Study: NCT06243666

Intervention type: BIOLOGICAL
Intervention: Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
Description: The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
Study: NCT05222919

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bare performance supplement
Description: dietary supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04460989

Intervention type: PROCEDURE
Intervention: arthroplasty
Description: total knee replacement

Intervention type: PROCEDURE
Intervention: arthroplasty
Description: total knee replacement
Study: NCT04962464

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peak Human Labs calorie mimetic supplement
Description: Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peak Human Labs calorie mimetic supplement
Description: Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peak Human Labs calorie mimetic supplement
Description: Supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Peak Human Labs calorie mimetic supplement
Description: Supplement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet
Description: Diet

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet
Description: Diet
Study: NCT05641168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adhesive material
Description: Newly developed adhesive material

Intervention type: OTHER
Group type: OTHER
Intervention: Standard adhesive material
Description: Standard adhesive material
Study: NCT06146348

Intervention type: BEHAVIORAL
Intervention: adapted DRAUP strategy bundle
Description: DRAUP deimplementation strategy bundle includes: 1) education and training, 2) supervision and in-person decision support, and 3) audit and feedback to target capability. Opportunity is addressed by 4) algorithm development and 5) organizational support. Finally, 6) facilitators and 7) planned adaptation after interval program assessment address the motivations needed to change behavior.

Intervention type: BEHAVIORAL
Intervention: adapted DRAUP strategy bundle
Description: DRAUP deimplementation strategy bundle includes: 1) education and training, 2) supervision and in-person decision support, and 3) audit and feedback to target capability. Opportunity is addressed by 4) algorithm development and 5) organizational support. Finally, 6) facilitators and 7) planned adaptation after interval program assessment address the motivations needed to change behavior.
Study: NCT05993078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% NaCl 2000ml
Description: The patient will undergo NS 2000ml intravenous infusion immediately after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl 200-400ml
Description: The patients receive an NS 200-400ml after IVT. Subsequent therapy is based on Chinese guidelines for diagnosis and treatment of acute ischemic stroke 2018. All of the subjects should be treated in the hospital at least 7 days according to the guidelines for early management of stroke.
Study: NCT05677334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Henagliflozin
Description: Combination therapy of Henagliflozin and Continuous Subcutaneous Insulin Infusion

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Subcutaneous Insulin Infusion
Description: Continuous Subcutaneous Insulin Infusion therapy alone

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion
Description: Continuous Subcutaneous Insulin Infusion therapy alone
Study: NCT06323824

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine (BUP)
Description: Drug: Buprenorphine (BUP)~Possible formulations:~A. Buprenorphine 225 mcg to 24 mg 225 mcg to 32 mg per day~B. Buprenorphine (Extended release) 300 mg q 28 days (Sublocade) 100 mg q 28 days (Sublocade) 8 mg q 7 days (Brixadi) 16 mg q 7 days (Brixadi) 24 mg q 7 days (Brixadi) 32 mg q 7 days (Brixadi) 64 mg q 7 28 days (Brixadi) 96 mg q 7 28 days (Brixadi) 128 mg q 7 28 days (Brixadi)
Study: NCT04852419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c5
Description: ZN-c5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c5
Description: ZN-c5
Study: NCT04793711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EpiCeram
Description: protective emollient
Study: NCT05479968

Intervention type: DEVICE
Intervention: Spectrocor device
Description: This feasibility study is intended to document the feasibility, safety, and usability of the Investigational device.
Study: NCT04559620

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maternal voice
Description: Maternal voice (song/ words) played in the incubator for 30mins x4/day x 7 days
Study: NCT05625711

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The endovascular interventional surgical instrument control system
Description: The endovascular interventional surgical instrument control system is based on the analysis of the operation behavior of doctors and their assistants in the process of manual intervention. It simulates the coordinated movement of four manipulators, completes the advance and retreat of the catheter and guide wire cavity, and realizes the different actions of wire feeding along the tube, wire feeding along the wire, wire twisting coordination, wire replacement, stent release, etc.
Study: NCT06252571

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: - Melatonin - Active light ttherapy
Description: 1 tablet per day, in the evening + morning light therapy over 6 weeks

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: - Placebo drug - Placebo light therapy
Description: 1 tablet per day in the evening + morning placebo light therapy
Study: NCT05958199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPX267
Description: NPX267 will be administered by intravenous infusion every three weeks until documented disease progression or participant withdrawal
Study: NCT06402747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: Clopidogrel 75mg once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: Cilostazol 200mg per day
Study: NCT05874128

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prospective evaluation of HeartFocus Device (Software)
Description: The primary objective of the study is to evaluate if exams, performed with the HeartFocus software by novices, are of sufficient quality to analyze visually
Study: NCT06012591

Intervention type: OTHER
Group type: OTHER
Intervention: Quality improvement recommendations (action plans)
Description: Developed and implemented at facility level to address key quality gaps emerging from the baseline assessment
Study: NCT05363124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEWS calculation by parents using AI-based smartphone app
Description: After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. Explanations will be given to the parents regarding the use of the application and the way to calculate the PEWS through a very brief and standardized education. Parents should then proceed to the calculation of PEWS, as far as possible before the intervention of the nurse, using the Caducy® appl with a smartphone dedicated to the study .

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEWS calculation by nurse using conventional procedure
Description: After patient registration, the patient will be installed in the nursing office with one of his parents . After screening a potential life-threatening patient for which treatment would be started first of all, the nurse will collect the signed parental consent for participating to the study. the nurse proceed to the calculation of PEWS in blind of parents and to triage process by priorityzing patient in 5 level of gravity (from 1-vital emergency to 5-nonurgent patient). If the medical examination was not proceeded directly after the triage process, nurses were asked to proceed a new triage if the optimal delay of the medical examination was passed.
Study: NCT06544798

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV2-hAQP1
Description: Administration of a prespecified concentration of AAV2-hAQP1 via Stensen's duct to each parotid gland
Study: NCT06528756

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shockwave therapy
Description: ESWT, these will be given using a 15 mm transmitter in mode continuous with pressure at 3 bar, frequency 12Hz and 3000 impacts. The number of sessions will be between 4 - 8 depending on the patient's clinic with a break between sessions of 5 to 10 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: shockwave therapy
Description: ESWT, these will be given using a 15 mm transmitter in mode continuous with pressure at 3 bar, frequency 12Hz and 3000 impacts. The number of sessions will be between 4 - 8 depending on the patient's clinic with a break between sessions of 5 to 10 days.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Barbotage
Description: US-PICT will be carried out with 1 session in which the following actions will be carried out:~* First, a suprascapular nerve block will be performed with a corticosteroid and anesthetic (3 ml of bupivacaine) in an ultrasound-guided manner.~* The calcification will then be infiltrated with 5 ml local lidocaine and preloaded physiological saline solution in an ultrasound-guided manner.~* Finally, repeated suctions will be performed with physiological saline solution to extract calcium in an ultrasound-guided way.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Barbotage
Description: US-PICT will be carried out with 1 session in which the following actions will be carried out:~* First, a suprascapular nerve block will be performed with a corticosteroid and anesthetic (3 ml of bupivacaine) in an ultrasound-guided manner.~* The calcification will then be infiltrated with 5 ml local lidocaine and preloaded physiological saline solution in an ultrasound-guided manner.~* Finally, repeated suctions will be performed with physiological saline solution to extract calcium in an ultrasound-guided way.
Study: NCT06309576

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting-refeeding cycle
Description: Participants will be maintained in metabolic chambers and exposed to 1 day of energy balance with a standard diet, 2 days of fasting (only water), and 2 days of ad-libitum refeeding using a liquid diet provided in hydration bladders to avoid portion control.
Study: NCT06523088

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PN20
Description: Six dose levels of PN20 will be evaluated
Study: NCT06224556

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Brief-MPI assessment (based on the Comprehensive Geriatric Assessment); Personalized Prevention Program
Description: Patients will be evaluated at baseline and at 6 and 12 months after the baseline through the CGA, the Resilience Scale (RS-14 items) and the Psychological General Wellbeing Index short form.~The prevention program will be received at the baseline, so at the two follow-ups patients wiil asked the adherence to it and the level of satisfaction (Client Satisfaction Questionnaire - 8 items).~Saliva sample will be collected and analyzed.
Study: NCT06390150

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal Cord Stimulation
Description: The spinal cord stimulator is an implantable pulse generator connected to electrodes with leads that stimulate the spinal cord. The device is programmed to deliver therapeutic stimulation to treat pain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: The spinal cord stimulator is an implantable pulse generator connected to electrodes with leads that stimulate the spinal cord. The device is programmed to deliver therapeutic stimulation to treat pain.
Study: NCT05045443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Curcumin
Description: Tumeric curcumin 500 mg per oral capsule of Puritans Pride company supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: As per institution protocol for Standard of nutritional Care

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: As per institution protocol for Standard of nutritional Care
Study: NCT04856267

Intervention type: DEVICE
Intervention: LINQ device - implantable cardiac monitor - referred to in the application as implantable loop recorder or ILR)
Description: Implantation of an implantable cardiac monitor device (brand name LINQ device, Medtronic) will be performed under local anaesthetic using an aseptic sterile technique. They will undergo frequent follow-up and monitoring for arrhythmias through remote monitoring of the device
Study: NCT05505435

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot-Medroxyprogestereone Acetate
Description: subcutaneous depot medroxyprogesterone acetate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Depot-Medroxyprogestereone Acetate
Description: intramuscular depot medroxyprogesterone acetate
Study: NCT05013710

Intervention type: OTHER
Intervention: Complete Clinical Interaction
Description: The intervention consists of a completed interaction with the mobile health clinic during the study periods, on which adequate evaluative data was collected on the patient visit (e.g. staff was able to note their visit and reason for visit, the patient met with an healthcare professional, etc)

Intervention type: OTHER
Intervention: Complete Clinical Interaction
Description: The intervention consists of a completed interaction with the mobile health clinic during the study periods, on which adequate evaluative data was collected on the patient visit (e.g. staff was able to note their visit and reason for visit, the patient met with an healthcare professional, etc)

Intervention type: OTHER
Intervention: Complete Clinical Interaction
Description: The intervention consists of a completed interaction with the mobile health clinic during the study periods, on which adequate evaluative data was collected on the patient visit (e.g. staff was able to note their visit and reason for visit, the patient met with an healthcare professional, etc)
Study: NCT05519917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Subjects will receive evaluations at the beginning of treatment, after every three cycles and at the end of the whole study.
Study: NCT06243666

Intervention type: OTHER
Intervention: No intervention
Description: No intervention was implemented.
Study: NCT06580015

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET-CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Flotufolastat F-18 Gallium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Undergo X1 RMRS PET-CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET-CT
Study: NCT06099613

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EG-COVII
Description: EG-COVII is a bivalent vaccine to prevent SARS-CoV-2 infection against wild type and Omicron variants
Study: NCT03950193

Intervention type: OTHER
Intervention: Questionnaires to evaluate psychic development of the child
Description: Child Behaviour Checklist. This test, completed by parents and with 52 questions, is designed to screen children at high risk for emotional problems, mood disorders, anxiety, pervasive developmental problems, attention deficit and hyperactivity, antonymic reactions (oppostion, provocation) and sleep problems.
Study: NCT05599529

Intervention type: OTHER
Intervention: Differential attainment
Description: Differential attainment related to covid, ethnicity and international graduate status

Intervention type: OTHER
Intervention: Differential attainment
Description: Differential attainment related to covid, ethnicity and international graduate status
Study: NCT05660746

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RoadMAB
Description: The RoadMAB Dashboard is a real-time decision support system that incorporates PK model-informed Bayesian estimation to provide precision dosing at the point of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Infliximab
Description: Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.~Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: Conventional dosing. Induction: 5-7.5 mg/kg at 0, 2, and 6 weeks. Maintenance: 5-10 mg/kg at every 4-8 weeks based on results of drug concentration monitoring for a flat target of 5-10 μg/mL.~Precision dosing. Induction: 5-12.5 mg/kg at 0, 2, and 6 weeks to target a week6 concentration of 18-24 μg/mL with dosing support provided by the RoadMABTM clinical decision support tool. Maintenance: 5-15 mg/kg every 4-8 weeks to achieve apriori pharmacokinetic and pharmacodynamic targets (CRP, disease activity scores and fecal calprotectin) with dosing support provided by the RoadMABTM clinical decision support tool.
Study: NCT05285878

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod
Description: 0.5 mg daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mg daily
Study: NCT06523088

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of PN20
Study: NCT04468776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: Zolpidem, as prescribed by physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem
Description: Zolpidem, as prescribed by physician

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: 6-week internet CBT-I multi-component intervention (SHUTi) including sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: 6-week internet CBT-I multi-component intervention (SHUTi) including sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone
Description: Trazodone, as prescribed by physician

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Trazodone, as prescribed by physician
Study: NCT06092606

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group:DH001 placebo
Description: Dosage: DH001 placebo (8 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trial group: DH001 low-dose group
Description: Dosage: DH001 200mg (4 tablets) + DH001 placebo (4 tablets)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trial group: DH001 high-dose group
Description: Dosage: DH001 400mg (8 tablets).